Developer docs
API playgroundTry for free, no card

Search company profiles

CatSci

Full company profile

uuid00083nt

Namestring
CatSci
Legal namestring
CatSci Ltd
Websiteurl
catsci.com
Company typeenum
Private
Founded yearint
2011
Descriptiontext

CatSci is a UK-based strategic contract research organisation (CRO) providing integrated drug substance development services to global pharmaceutical and biotechnology companies. Founded in 2010 from the scientific heritage of AstraZeneca's Avonmouth site, CatSci operates across three UK locations — Cardiff (headquarters), London, and Nottingham (its largest operational hub) — and serves seven of the top ten global pharmaceutical companies alongside a growing base of biotech clients (55% of new projects). The company employs 51-100 staff, 80% of whom hold PhDs, and organises its work around six therapeutic modalities — small molecules, oligonucleotides, peptides, TACs and molecular glues, hybrid modalities, and complex synthetic medicines — spanning the full development lifecycle from design-make-test-select through IND-enabling work, clinical-phase process development, GMP manufacturing transition, and post-approval support.

The technology backbone is CatSci's proprietary CHETAH platform (Cheminformatics and Hierarchical Analysis), which integrates high-throughput experimentation (HTE), Design of Experiments (DoE), Bayesian optimisation, and Visual AI tools (delivered via partnership with Reach Industries' Lumi product) into a single decision-support workflow for solvent selection, route scouting, and process optimisation. CatSci holds granted patents in biocatalysis and catalysis, operates a SafeBridge-certified OEB-5 HPAPI laboratory, and holds ISO 27001, EcoVadis Silver, and My Green Lab certifications. The 2024 acquisition of Reach Separations extended separation science and chromatographic purification from milligrams to kilograms.

CatSci generates revenue through bespoke, project-based fee-for-service contracts with multi-year terms, priced per engagement based on scope, complexity, and duration. The go-to-market model is direct enterprise field sales targeting pharmaceutical procurement, R&D, and manufacturing teams, supplemented by participation in industry events such as CPhI Worldwide and content-driven inbound marketing. Customer segments span large pharma (primary), emerging and mid-sized biotech (growing), and fellow CROs/CDMOs seeking specialist capabilities. CatSci is privately held, backed by Keensight Capital since June 2022, and co-founded by Dr. Ross Burn (CEO) and Dr. Simon Tyler (CCO), who remain in active leadership.

Short descriptiontext

CatSci is a UK-based contract research organisation providing integrated drug substance development services from discovery to GMP manufacturing for global pharmaceutical and biotechnology companies, with proprietary CHETAH digital platform and specialist capabilities in HPAPI, peptides, oligonucleotides, and hybrid modalities.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersCardiff, United Kingdom
HQ citystring
Cardiff
HQ countrystring
United Kingdom
HQ regionstring
Europe
Markets served

Serves global market

Offices3 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
pharmaceutical contract research, drug substance development, process development services, API manufacturing services, small molecule development
Industry4 codes
PRIMARYHLAGAHAA
Small-Molecule API Process Development & Route Scouting
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/API & Small-Molecule Development/Manufacturing Services
SECONDARYHLAIALAD
CMC & Pharmaceutical Development (Formulation/Process/Analytical Development)
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Research and Development
SECONDARYHLAGAJAO
AI/ML Platforms for Drug Discovery & Experiment Optimization
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
SECONDARYHLAIALAH
Regulatory Strategy & IND/NDA/BLA Submissions Support
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Research and Development
NAICS code2 codes
  • Research and Development in the Physical, Engineering, and Life Sciences54171
  • Scientific Research and Development Services5417
SIC code1 code
  • Services-Commercial Physical & Biological Research8731
Product category
Pharmaceutical Contract Research Services
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model1 record
1Contract Research Services
TypeProfessional Services
Description

CatSci generates revenue through bespoke contract research and development services for the pharmaceutical industry. Projects are conducted under fee-for-service arrangements, typically contracted for specific stages of drug substance development (e.g., route scouting, process development, scale-up). Revenue is project-based and non-recurring in nature, with contracts ranging from short-term studies to multi-phase programmes.

Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Personnel, Technology or R&D, Infrastructure, Operations, Marketing or Sales, Supply Chain
Pricing details1 tier
1Custom project-based pricing
ModelOtherBilling cadenceMulti-year contract
Notes

Pricing is negotiated on a per-project basis reflecting the scope, complexity, duration, and resources required for each contract research engagement. No public price list or tier structure is available.

GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

CatSci is a UK-based strategic outsourcing partner providing integrated contract research and development services for drug substance development, spanning from early discovery through to GMP manufacturing. Services cover route selection, process development, analytical services, purification and separation science, catalysis and enabling chemistry, GMP drug substance manufacturing, translational bioscience, and high-throughput experimentation across modalities including small molecules, oligonucleotides, peptides, TACs and molecular glues, hybrid modalities, and complex synthetic medicines. The proprietary CHETAH digital platform integrates cheminformatics, Design of Experiments, Bayesian optimisation, robotic execution, automated analytics, and visual AI to accelerate data-driven process decisions.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 value
  • HP API market projected to exceed $75 billion by 2030, indicating significant growth opportunity for integrated drug substance service providers like CatSci.
Product overview1 text field

CatSci is a UK-based strategic outsourcing partner offering integrated R&D services for drug development, spanning from early discovery through to GMP manufacturing. The company operates as a unified platform combining multiple scientific disciplines including chemistry, bioscience, analytical science, process development, and purification. The core offerings include: CHETAH (digital integration platform), Route Selection Services, Analytical Services, Purification and Separation Science, Process Development, GMP Drug Substance Manufacturing, Catalysis and Enabling Chemistry, High-Throughput Experimentation, and Translational Bioscience. These are organized around therapeutic modalities including Small Molecules, Oligonucleotides, Peptides, TACs and Molecular Glues, Hybrid Modalities, and Complex Synthetic Medicines. Additional integrated workflows include Design-Make-Test-Select and digital tools like the Route Costing Calculator. CatSci expanded its capabilities through strategic acquisitions (Reach Separations for purification expertise) and facility expansions (HPAPI labs, peptide labs, bioscience labs).

Product and service14 records
1Route Selection Services
CategoryDrug Substance Development Services
Description

Synthetic route selection and evaluation service that balances cost, chance of technical success, sustainability, and manufacturability using retrosynthetic planning, parallel route scouting, and PMI modelling. Designed for pharmaceutical and biotech customers developing novel small molecule APIs.

2Analytical Services
3Purification and Separation Science
CategoryDrug Substance Development Services
Description

High-quality chromatographic solutions spanning analytical purification, preparative chromatography, and SFC for small molecules, oligonucleotides, peptides, and complex synthetics from milligrams to kilograms. Enhanced by the 2024 Reach Separations acquisition.

4Process Development
5GMP Drug Substance Manufacturing
6Catalysis and Enabling Chemistry
7High-Throughput Experimentation (HTE)
8Translational Bioscience
CategoryBioscience Services
Description

Assay development and screening services including target engagement, functional cell-based and phenotypic assays, translational models (2D/3D, iPSC), Direct-to-Biology screening, and data integration for drug discovery decision-making. Supports biotech and pharma customers across multiple therapeutic modalities.

9Small Molecule Development
10Oligonucleotide Development Services
11Peptide Development Services
CategoryTherapeutic Modality Services
Description

Complex peptide synthesis, modification, and purification for linear, cyclic, constrained, stapled, and conjugated peptides using automated SPPS platforms and advanced analytical support. Supports the peptide R&D group established January 2025 and dedicated peptide laboratory opened June 2025.

12TACs and Molecular Glues
13Hybrid Modality Development Services
14Complex Synthetic Medicines
Scale indicator5 records

Each record includes

Type, Value, Description, Source

Partnership3 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-01-01
Description

CatSci acquired Reach Separations in 2024, significantly expanding its separation science capabilities. The acquisition strengthens CatSci's ability to offer integrated drug substance development including advanced purification and separation services.

Strategic tierMajorTypeStrategic or Co-development Partner
Description

AGC Pharma Chemicals Europe S.L.U. is a strategic manufacturing partner for GMP manufacturing of HPAPIs and potent compounds. The partnership complements CatSci's process development capabilities with large-scale GMP manufacturing capacity, enabling end-to-end drug substance services for clients.

Strategic tierSupportingTypeTechnology or Integration
Description

CatSci partners with Reach Industries to integrate visual AI tools into its high-throughput experimentation and process monitoring workflows. This partnership enhances CatSci's digital chemistry capabilities by applying AI-driven visual analysis to chemical processes.

Recent move11 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight7 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Hovione is a closely comparable contract development and manufacturing organisation focused on small molecule API process development, particle engineering, and GMP manufacturing. Like CatSci, it serves global pharma and biotech customers with integrated drug substance services and emphasises enabling chemistries.

TypeDirect peer
Description

Sai Life Sciences is an India-headquartered CRO/CDMO offering drug substance development, process R&D, and GMP manufacturing for global pharma and biotech. Its integrated discovery-to-manufacturing model and customer base of large pharma are directly comparable to CatSci's positioning.

3Syngene International
TypeDirect peer
Description

Syngene is an India-based contract research and manufacturing organisation providing discovery, process development, and GMP manufacturing services to global pharma. Like CatSci, it serves top-tier pharma clients with integrated scientific and digital capabilities.

TypeBroad incumbent
Description

Eurofins CDMO provides API development, process R&D, and GMP manufacturing services as part of the broader Eurofins scientific services portfolio. It competes with CatSci in small molecule process development while operating at considerably larger scale across global sites.

TypeBroad incumbent
Description

Cambrex is a major CDMO providing small molecule API development, process optimisation, and commercial GMP manufacturing for global pharma. It represents a larger, established incumbent competing with CatSci for the same route scouting and process development programmes.

TypeDirect peer
Description

Carbogen Amcis is a Swiss-headquartered CDMO providing API development, process R&D, and GMP manufacturing for highly potent and conventional APIs. Its service scope (route scouting, process optimisation, GMP scale-up) closely mirrors CatSci's core offering.

TypeBroad incumbent
Description

Piramal Pharma Solutions is a large global CDMO offering API development, HPAPI manufacturing, and commercial-scale GMP services. It is a broader incumbent in the same drug substance development space as CatSci, with substantially greater scale.

TypeDirect peer
Description

Pharmaron is a global CRO/CDMO offering integrated drug discovery, process chemistry, API development, and GMP manufacturing for small molecules and biologics. Its end-to-end service portfolio and global pharma/biotech customer base directly parallel CatSci's offering and growth model.

TypeBroad incumbent
Description

Lonza is one of the world's largest CDMOs, offering API development and manufacturing across small molecules, biologics, and emerging modalities. While much larger, it competes with CatSci for outsourced small molecule process development work and represents the upper bound of CDMO scale in the space.

TypeDirect peer
Description

Ascensus Specialties (the former Johnson Matthey Health Materials business) is a US-based CDMO focused on small molecule API development, custom synthesis, and GMP manufacturing. Its scope of services around route scouting, process optimisation, and HPAPI handling closely overlaps with CatSci's.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers1 record

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

Integration1 record

Each record includes

Title, Type, Description, Source

AI capability7 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles9 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries1 record

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance4 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds1 record

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors1 record

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

CatSci

Pharmaceutical Contract Research Servicescatsci.com

CatSci is a UK-based contract research organisation providing integrated drug substance development services from discovery to GMP manufacturing for global pharmaceutical and biotechnology companies, with proprietary CHETAH digital platform and specialist capabilities in HPAPI, peptides, oligonucleotides, and hybrid modalities.

What CatSci does

CatSci is a UK-based strategic contract research organisation (CRO) providing integrated drug substance development services to global pharmaceutical and biotechnology companies. Founded in 2010 from the scientific heritage of AstraZeneca's Avonmouth site, CatSci operates across three UK locations — Cardiff (headquarters), London, and Nottingham (its largest operational hub) — and serves seven of the top ten global pharmaceutical companies alongside a growing base of biotech clients (55% of new projects). The company employs 51-100 staff, 80% of whom hold PhDs, and organises its work around six therapeutic modalities — small molecules, oligonucleotides, peptides, TACs and molecular glues, hybrid modalities, and complex synthetic medicines — spanning the full development lifecycle from design-make-test-select through IND-enabling work, clinical-phase process development, GMP manufacturing transition, and post-approval support.

The technology backbone is CatSci's proprietary CHETAH platform (Cheminformatics and Hierarchical Analysis), which integrates high-throughput experimentation (HTE), Design of Experiments (DoE), Bayesian optimisation, and Visual AI tools (delivered via partnership with Reach Industries' Lumi product) into a single decision-support workflow for solvent selection, route scouting, and process optimisation. CatSci holds granted patents in biocatalysis and catalysis, operates a SafeBridge-certified OEB-5 HPAPI laboratory, and holds ISO 27001, EcoVadis Silver, and My Green Lab certifications. The 2024 acquisition of Reach Separations extended separation science and chromatographic purification from milligrams to kilograms.

CatSci generates revenue through bespoke, project-based fee-for-service contracts with multi-year terms, priced per engagement based on scope, complexity, and duration. The go-to-market model is direct enterprise field sales targeting pharmaceutical procurement, R&D, and manufacturing teams, supplemented by participation in industry events such as CPhI Worldwide and content-driven inbound marketing. Customer segments span large pharma (primary), emerging and mid-sized biotech (growing), and fellow CROs/CDMOs seeking specialist capabilities. CatSci is privately held, backed by Keensight Capital since June 2022, and co-founded by Dr. Ross Burn (CEO) and Dr. Simon Tyler (CCO), who remain in active leadership.

CatSci firmographics

Firmographics
Name
CatSci
Legal name
CatSci Ltd
Website
https://catsci.com
Company type
Private
Founded year
2011
Operating status
Operating
Headcount range
51–100 employees
Short description
CatSci is a UK-based contract research organisation providing integrated drug substance development services from discovery to GMP manufacturing for global pharmaceutical and biotechnology companies, with proprietary CHETAH digital platform and specialist capabilities in HPAPI, peptides, oligonucleotides, and hybrid modalities.
Ownership category
akta.pro rank

CatSci industry classification

Industry
Product category
Pharmaceutical Contract Research Services
NAICS
Research and Development in the Physical, Engineering, and Life Sciences (54171), Scientific Research and Development Services (5417)
SIC
Services-Commercial Physical & Biological Research (8731)
akta.pro industry
PRIMARYHLAGAHAA
Small-Molecule API Process Development & Route Scouting
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/API & Small-Molecule Development/Manufacturing Services
SECONDARYHLAIALAD
CMC & Pharmaceutical Development (Formulation/Process/Analytical Development)
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Research and Development
SECONDARYHLAGAJAO
AI/ML Platforms for Drug Discovery & Experiment Optimization
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
SECONDARYHLAIALAH
Regulatory Strategy & IND/NDA/BLA Submissions Support
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Research and Development

Keywords

  • Pharmaceutical contract research
  • Drug substance development
  • Process development services
  • API manufacturing services
  • Small molecule development

Where CatSci is headquartered

Location

Headquarters

HQ city
Cardiff
HQ country
United Kingdom
HQ region
Europe

Offices3 records

Markets served

CatSci business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Technology or R&D, Infrastructure, Operations, Marketing or Sales, Supply Chain

Revenue model

  1. Contract Research Services: CatSci generates revenue through bespoke contract research and development services for the pharmaceutical industry. Projects are conducted under fee-for-service arrangements, typically contracted for specific stages of drug substance development (e.g., route scouting, process development, scale-up). Revenue is project-based and non-recurring in nature, with contracts ranging from short-term studies to multi-phase programmes.

Pricing tiers

ModelBillingPrice
OtherMulti-year contractCustom project-based pricing

Go-to-market motion2 records

Distribution channels1 record

Marketing channels5 records

CatSci product offering

Product offering

Core offering

CatSci is a UK-based strategic outsourcing partner providing integrated contract research and development services for drug substance development, spanning from early discovery through to GMP manufacturing. Services cover route selection, process development, analytical services, purification and separation science, catalysis and enabling chemistry, GMP drug substance manufacturing, translational bioscience, and high-throughput experimentation across modalities including small molecules, oligonucleotides, peptides, TACs and molecular glues, hybrid modalities, and complex synthetic medicines. The proprietary CHETAH digital platform integrates cheminformatics, Design of Experiments, Bayesian optimisation, robotic execution, automated analytics, and visual AI to accelerate data-driven process decisions.

Product overview

CatSci is a UK-based strategic outsourcing partner offering integrated R&D services for drug development, spanning from early discovery through to GMP manufacturing. The company operates as a unified platform combining multiple scientific disciplines including chemistry, bioscience, analytical science, process development, and purification. The core offerings include: CHETAH (digital integration platform), Route Selection Services, Analytical Services, Purification and Separation Science, Process Development, GMP Drug Substance Manufacturing, Catalysis and Enabling Chemistry, High-Throughput Experimentation, and Translational Bioscience. These are organized around therapeutic modalities including Small Molecules, Oligonucleotides, Peptides, TACs and Molecular Glues, Hybrid Modalities, and Complex Synthetic Medicines. Additional integrated workflows include Design-Make-Test-Select and digital tools like the Route Costing Calculator. CatSci expanded its capabilities through strategic acquisitions (Reach Separations for purification expertise) and facility expansions (HPAPI labs, peptide labs, bioscience labs).

Differentiator

Problem solved

Functional benefit

Products and services

  • Route Selection Services Synthetic route selection and evaluation service that balances cost, chance of technical success, sustainability, and manufacturability using retrosynthetic planning, parallel route scouting, and PMI modelling. Designed for pharmaceutical and biotech customers developing novel small molecule APIs.
  • Analytical Services
  • Purification and Separation Science High-quality chromatographic solutions spanning analytical purification, preparative chromatography, and SFC for small molecules, oligonucleotides, peptides, and complex synthetics from milligrams to kilograms. Enhanced by the 2024 Reach Separations acquisition.
  • Process Development
  • GMP Drug Substance Manufacturing
  • Catalysis and Enabling Chemistry
  • High-Throughput Experimentation (HTE)
  • Translational Bioscience Assay development and screening services including target engagement, functional cell-based and phenotypic assays, translational models (2D/3D, iPSC), Direct-to-Biology screening, and data integration for drug discovery decision-making. Supports biotech and pharma customers across multiple therapeutic modalities.
  • Small Molecule Development
  • Oligonucleotide Development Services
  • Peptide Development Services Complex peptide synthesis, modification, and purification for linear, cyclic, constrained, stapled, and conjugated peptides using automated SPPS platforms and advanced analytical support. Supports the peptide R&D group established January 2025 and dedicated peptide laboratory opened June 2025.
  • TACs and Molecular Glues
  • Hybrid Modality Development Services
  • Complex Synthetic Medicines

Quantifiable outcome

  • HP API market projected to exceed $75 billion by 2030, indicating significant growth opportunity for integrated drug substance service providers like CatSci.

Companies that use CatSci

Customer profile

Named customers1 record

Segments3 records

Ideal customer profiles3 records

CatSci technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Integration1 record

AI capability7 records

Feature5 records

CatSci partnerships and signals

Strategic signal

Partnerships

Three partnerships are on record, tiered core, major and supporting.

  • Reach SeparationscoreStrategic or Co-development Partner · 1 January 2024CatSci acquired Reach Separations in 2024, significantly expanding its separation science capabilities. The acquisition strengthens CatSci's ability to offer integrated drug substance development including advanced purification and separation services.
  • AGC Pharma Chemicals Europe S.L.U.majorStrategic or Co-development PartnerAGC Pharma Chemicals Europe S.L.U. is a strategic manufacturing partner for GMP manufacturing of HPAPIs and potent compounds. The partnership complements CatSci's process development capabilities with large-scale GMP manufacturing capacity, enabling end-to-end drug substance services for clients.
  • Reach IndustriessupportingTechnology or IntegrationCatSci partners with Reach Industries to integrate visual AI tools into its high-throughput experimentation and process monitoring workflows. This partnership enhances CatSci's digital chemistry capabilities by applying AI-driven visual analysis to chemical processes.

Scale indicators5 records

Recent moves11 records

Expansion highlights7 records

CatSci competitors and assessment

Company assessment

Direct peers

  • Hovione: Hovione is a closely comparable contract development and manufacturing organisation focused on small molecule API process development, particle engineering, and GMP manufacturing. Like CatSci, it serves global pharma and biotech customers with integrated drug substance services and emphasises enabling chemistries.
  • Sai Life Sciences: Sai Life Sciences is an India-headquartered CRO/CDMO offering drug substance development, process R&D, and GMP manufacturing for global pharma and biotech. Its integrated discovery-to-manufacturing model and customer base of large pharma are directly comparable to CatSci's positioning.
  • Syngene International: Syngene is an India-based contract research and manufacturing organisation providing discovery, process development, and GMP manufacturing services to global pharma. Like CatSci, it serves top-tier pharma clients with integrated scientific and digital capabilities.
  • Carbogen Amcis: Carbogen Amcis is a Swiss-headquartered CDMO providing API development, process R&D, and GMP manufacturing for highly potent and conventional APIs. Its service scope (route scouting, process optimisation, GMP scale-up) closely mirrors CatSci's core offering.
  • Pharmaron: Pharmaron is a global CRO/CDMO offering integrated drug discovery, process chemistry, API development, and GMP manufacturing for small molecules and biologics. Its end-to-end service portfolio and global pharma/biotech customer base directly parallel CatSci's offering and growth model.
  • Ascensus Specialties: Ascensus Specialties (the former Johnson Matthey Health Materials business) is a US-based CDMO focused on small molecule API development, custom synthesis, and GMP manufacturing. Its scope of services around route scouting, process optimisation, and HPAPI handling closely overlaps with CatSci's.

Broad incumbents

  • Eurofins CDMO: Eurofins CDMO provides API development, process R&D, and GMP manufacturing services as part of the broader Eurofins scientific services portfolio. It competes with CatSci in small molecule process development while operating at considerably larger scale across global sites.
  • Cambrex: Cambrex is a major CDMO providing small molecule API development, process optimisation, and commercial GMP manufacturing for global pharma. It represents a larger, established incumbent competing with CatSci for the same route scouting and process development programmes.
  • Piramal Pharma Solutions: Piramal Pharma Solutions is a large global CDMO offering API development, HPAPI manufacturing, and commercial-scale GMP services. It is a broader incumbent in the same drug substance development space as CatSci, with substantially greater scale.
  • Lonza: Lonza is one of the world's largest CDMOs, offering API development and manufacturing across small molecules, biologics, and emerging modalities. While much larger, it competes with CatSci for outsourced small molecule process development work and represents the upper bound of CDMO scale in the space.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

CatSci social profiles

Digital presence

CatSci compliance and trust

Trust signal

Compliance4 records

CatSci financial estimates

Financial estimate

Revenue estimate

Valuation estimate

CatSci leadership team

Management profile

Number of profiles

Profiles9 records

CatSci subsidiaries and ownership

Company hierarchy

Subsidiaries1 record

CatSci funding detail

Funding detail

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

CatSci M&A and investment

M&A and investment

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about CatSci

What does CatSci do?

CatSci is a UK-based strategic outsourcing partner providing integrated contract research and development services for drug substance development, spanning from early discovery through to GMP manufacturing. Services cover route selection, process development, analytical services, purification and separation science, catalysis and enabling chemistry, GMP drug substance manufacturing, translational bioscience, and high-throughput experimentation across modalities including small molecules, oligonucleotides, peptides, TACs and molecular glues, hybrid modalities, and complex synthetic medicines. The proprietary CHETAH digital platform integrates cheminformatics, Design of Experiments, Bayesian optimisation, robotic execution, automated analytics, and visual AI to accelerate data-driven process decisions.

Is CatSci a public or private company?

CatSci is a private company. It is classified as private equity controlled and is currently operating.

When was CatSci founded?

CatSci was founded in 2011. It employs 51 to 100 people.

Where is CatSci based?

CatSci is headquartered in Cardiff, United Kingdom, in the Europe region.

How does CatSci make money?

One revenue line is on record: contract Research Services.

Who are CatSci's main competitors?

Direct peers on record are Hovione, Sai Life Sciences, Syngene International, Carbogen Amcis, Pharmaron and Ascensus Specialties. Broad incumbents are Eurofins CDMO, Cambrex, Piramal Pharma Solutions and Lonza.

Does CatSci have an API?

No public API is recorded for CatSci.

What industry is CatSci in?

CatSci's product category is Pharmaceutical Contract Research Services. Its primary akta.pro industry code is HLAGAHAA, Small-Molecule API Process Development & Route Scouting, with a secondary code of HLAIALAD, CMC & Pharmaceutical Development (Formulation/Process/Analytical Development). Its NAICS code is 54171 and its SIC code is 8731.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
ChromatographyonlineTackling Moisture Sensitivity in Oligonucleotide Synthesis: Novel Application of GC-VUV DetectionThe article presents a webinar demonstrating the application of Gas Chromatography coupled with LUMA’s vacuum ultraviolet (VUV) detection for monitoring moisture in oligonucleotide synthesis. It highlights how this method addresses the limitations of traditional Karl Fischer titration by providing precise, sensitive quantification to improve yield and purity. The session features speakers from CatSci Ltd discussing practical considerations and case studies for analytical scientists in the field.openPR.comLeading Companies Reinforce Their Presence in the HP (High Potency) APIs MarketThe HP (High Potency) APIs market is projected to reach $42.56 billion by 2030, growing at a compound annual growth rate of 9.4%, driven by increasing use in oncology and hormonal treatments and expanding contract manufacturing. In July 2025, Spain-based ESTEVE Pharmaceuticals, S.A. completed the acquisition of U.S.-based Regis Technologies Inc., a contract development and manufacturing organization specializing in HP APIs, aiming to bolster its U.S. footprint and manufacturing capabilities. Additionally, UK-based CatSci Ltd. partnered with AGC Pharma Chemicals Europe S.L.U. in March 2023 to offer expanded manufacturing processes including fluorination and bromination.InsidermediaCatSci makes strategic acquisition of Reach SeparationsCatSci has acquired Reach Separations to enhance its chromatographic services for global customers. This strategic acquisition is aimed at improving CatSci's capabilities in Chemistry, Manufacturing and Controls (CMC) and marks a significant milestone in its growth strategy. The integration is expected to facilitate better analytical development from discovery to manufacture, benefiting customers by providing comprehensive services.SpecchemonlineCatSci buys Reach SeparationsDrug development services supplier CatSci has acquired its UK-based competitor Reach Separations, with the transaction supported by private equity manager Keensight Capital. The acquisition involves the full transfer and integration of Reach Separations' laboratories in the UK and France, expanding CatSci's chromatographic service capabilities.PharmiWeb.comKeensight Capital invests in Cardiff-Based CatSci LtdKeensight Capital has invested in CatSci Ltd, a Cardiff-based Contract Research Organisation (CRO) that supports global pharmaceutical companies. The investment aims to accelerate CatSci's growth through organic expansion and accretive M&A, leveraging Keensight's expertise in the CRDMO space. This funding will support the company's continued expansion of its workforce, laboratories, and service offerings.